Cidara Therapeutics Stock Alpha and Beta Analysis
| CDTX Stock | USD 20.21 0.01 0.05% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cidara Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cidara Therapeutics over a specified time horizon. Remember, high Cidara Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cidara Therapeutics' market risk premium analysis include:
Beta 0.39 | Alpha 0.7 | Risk 4.17 | Sharpe Ratio 0.23 | Expected Return 0.95 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cidara |
Cidara Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cidara Therapeutics market risk premium is the additional return an investor will receive from holding Cidara Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cidara Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cidara Therapeutics' performance over market.| α | 0.70 | β | 0.39 |
Cidara Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cidara Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Cidara Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cidara Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Cidara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cidara Therapeutics shares will generate the highest return on investment. By understating and applying Cidara Therapeutics stock market price indicators, traders can identify Cidara Therapeutics position entry and exit signals to maximize returns.
Cidara Therapeutics Return and Market Media
The median price of Cidara Therapeutics for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 11.7 with a coefficient of variation of 19.88. The daily time series for the period is distributed with a sample standard deviation of 2.52, arithmetic mean of 12.66, and mean deviation of 1.81. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Spencer Ryan of 2125 shares of Cidara Therapeutics at 12.64 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 909 shares by Les Tari of Cidara Therapeutics at 11.6393 subject to Rule 16b-3 | 09/11/2024 |
3 | Cidara Therapeutics executive sells over 10k in company stock - Investing.com | 09/13/2024 |
4 | Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts | 09/19/2024 |
5 | How to Take Advantage of moves in - Stock Traders Daily | 09/24/2024 |
6 | Acquisition by Shane Ward of 135540 shares of Cidara Therapeutics at 10.75 subject to Rule 16b-3 | 09/30/2024 |
7 | Shattuck Labs stock craters following pipeline and job cuts | 10/02/2024 |
8 | Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 | 10/16/2024 |
9 | Cidara Therapeutics Q3 Earnings Snapshot | 11/07/2024 |
10 | Cidara Therapeutics Unique Cloudbreak Platform And Its Promise In Influenza And Oncology | 11/14/2024 |
11 | Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference | 11/19/2024 |
12 | Cidara Therapeutics Announces 105 Million Private Placement | 11/21/2024 |
13 | Acquisition by Ra Capital Management, L.p. of 389716 shares of Cidara Therapeutics at 14.912 subject to Rule 16b-3 | 11/26/2024 |
14 | RA CAPITAL MANAGEMENT, L.P. Increases Stake in Cidara Therapeutics Inc | 11/27/2024 |
About Cidara Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cidara or other stocks. Alpha measures the amount that position in Cidara Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 55.69 | 12.63 | 14.89 | 14.14 | Receivables Turnover | 9.26 | 11.02 | 3.93 | 3.74 |
Cidara Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cidara Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cidara Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cidara Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cidara Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cidara Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cidara Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.